Key result
Combined therapy with 4 g omega-3-PUFAs and 10 mg rosuvastatin significantly improved endothelial-dependent vasodilation (-1.42% to 11.36%, p=0.001) compared to rosuvastatin alone.
Why the study?
Does adding omega-3-PUFAs to rosuvastatin improve endothelial function and lipid profiles in South Asians with dyslipidemia?
Population
n=30 South Asian subjects with dyslipidemia and endothelial dysfunction
Comparison
Rosuvastatin 10 mg and omega-3-PUFAs 4 g daily vs Rosuvastatin 10 mg alone
Design
RCT, randomized (crossover design)
Follow-up
8 weeks
Authors
Loading...
Improves endothelial function when added to rosuvastatin in South Asians with dyslipidemia; extends combination therapy evidence to this population.
RCT (n=30)
Does adding omega-3-PUFAs to rosuvastatin improve endothelial function and lipid profiles in South Asians with dyslipidemia?
p-value: p=0.001
The addition of high-dose omega-3 fatty acids to rosuvastatin significantly improves endothelial function and lipid profiles in South Asians with dyslipidemia.
Catalin Mindrescu (2008) conducted an RCT in dyslipidemia and endothelial dysfunction (n=30). Omega-3-PUFAs plus rosuvastatin vs. rosuvastatin 10 mg alone was evaluated on endothelial-dependent vasodilation (EDV) (p=0.001). Combined therapy with 4 g omega-3-PUFAs and 10 mg rosuvastatin significantly improved endothelial-dependent vasodilation (-1.42% to 11.36%, p=0.001) compared to rosuvastatin alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: